Exact Ventures
1325 Howard Avenue, Suite 267, Burlingame, CA, 94010, United States
Overview
Exact Ventures is an independent market intelligence and strategic consulting firm that offers a holistic, analytical view of emerging and transitioning technology wireless markets. Client deliverables, typically consisting of quarterly or biannual market share and forecast reports, are both strategic and highly quantitative. Exact Ventures collaborates with our clients to benchmark their own performance and the performance of their competitors, to quantify new and transitioning technology markets, and access changes to business models and go-to-market strategies. Our work is a reflection of our passion for technology, analytics, accuracy, and adding value to our clients. Information sources include the following: Primary research •Surveys, interviews, and briefings with vendors •Interviews and briefings with service and content providers •Interviews and briefings with component and other ecosystem suppliers Secondary research •Vendor financial statements, earnings calls, investor presentations •Service provider financial statements, key performance indicators, earnings calls, and investor and technology presentations •Demographic data •Economic, government, and regulatory data
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Market Research
Investment portfolio
- Haystack Oncology
Participated · Series A · Nov 2022
Haystack Oncology is developing an ultrasensitive, personalized ctDNA-based minimal residual disease (MRD) diagnostic that can detect as few as one mutant molecule in a million DNA molecules. Its Haystack Duo™ platform uses low-error next-generation chemistry and a tumor-informed liquid-biopsy workflow beginning with tissue-based whole-exome sequencing to identify patient-specific tumor mutations and create personalized MRD tests. The company was co-founded in 2021 by Drs. Bert Vogelstein, Ken Kinzler and Nick Papadopoulos, and Joshua Cohen, alongside CEO Dan Edelstein and CTO Dr. Frank Holtrup. Haystack is based in Baltimore, Maryland, with research facilities in Hamburg, Germany. In November 2022 it raised $56M in a Series A led by Catalio Capital Management with participation from Bruker, Exact Ventures and Alexandria Venture Investments to fund continued development and a planned 2023 commercialization of its test. As part of the round, Isaac Ro joined the board as Executive Chairman and Dr. Diamantis Xylas joined as a board observer; Catalio founders George Petrocheilos and Dr. Jacob Vogelstein also serve on the board.
Team
No current team members are available.